Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immunotherapies - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Drug Profile

Research programme: immunotherapies - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Alternative Names: Immuno-oncology therapeutics - Immune-Onc Therapeutics/The University of Texas Health Science Center at Houston/The University of Texas Southwestern Medical Center

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune-Onc Therapeutics; University of Texas Health Science Center at Houston; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Leukocyte-associated immunoglobulin-like receptor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Immunological disorders

Most Recent Events

  • 12 Mar 2020 No development reported for Immunological disorders in USA (Parenteral)
  • 12 Mar 2020 Preclinical trials in Cancer in USA (Parenteral) before March 2020 (Immune-Onc Therapeutics pipeline March 2020)
  • 18 Apr 2017 Immune-Onc Therapeutics enters into an exclusive license and collaboration agreement with University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center to develop biotherapeutics for Cancer and other Immunological disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top